PolyPid grants 75,000 stock options to executive

PolyPid Ltd. granted its Deputy CEO, EVP, RD, CRA, Dalit Fellous Hazan 75,000 stock options on May 11, 2026, with an exercise price of $4.4600 per share for 75,000 Ordinary Shares.

Accepted by SEC EDGAR 07/17/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. granted its Deputy CEO, EVP, RD, CRA, Dalit Fellous Hazan 75,000 stock options on May 11, 2026, with an exercise price of $4.4600 per share for 75,000 Ordinary Shares.

The options vest on a quarterly basis from May 11, 2026 until May 11, 2030 and expire on May 11, 2036; following this grant she holds 75,000 options directly.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Hazan Dalit Fellous

Role Deputy CEO, EVP, RD, CRA

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	75,000	$4.46	$335K

Holdings After Transaction: Stock option (right to buy) — 75,000 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 75,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

Key Figures

Stock options granted: 75,000 options Exercise price: $4.4600 per share Underlying Ordinary Shares: 75,000 shares +4 more

7 metrics

Stock options granted 75,000 options Grant to Deputy CEO Dalit Fellous Hazan on May 11, 2026

Exercise price $4.4600 per share Exercise price of the granted stock options

Underlying Ordinary Shares 75,000 shares Ordinary Shares underlying the granted options

Expiration date May 11, 2036 Options expire on this date

Vesting period start May 11, 2026 Options vest quarterly beginning on this date

Vesting period end May 11, 2030 Options vest quarterly until this date

Holdings after grant 75,000 options Total derivative securities held directly after this transaction

Key Terms

Stock option (right to buy), exercise price, vesting, Ordinary Shares, +1 more

5 terms

Stock option (right to buy) financial

"Security title reported as Stock option (right to buy)"

exercise price financial

"Conversion or exercise price reported as $4.4600 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options vest on a quarterly basis beginning May 11, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"Underlying security title identified as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

expiration date financial

"Expiration date for the options is May 11, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PolyPid (PYPD) report on May 11, 2026?

PolyPid reported a grant of 75,000 stock options to Deputy CEO Dalit Fellous Hazan on May 11, 2026. The options relate to 75,000 Ordinary Shares and were awarded at an exercise price of $4.4600 per share as a derivative security grant.

How many PolyPid (PYPD) stock options were granted to Dalit Fellous Hazan?

Dalit Fellous Hazan received 75,000 stock options in this transaction. These options are exercisable into 75,000 Ordinary Shares of PolyPid Ltd., and following the grant her directly held derivative position reported in this filing totals 75,000 options.

What is the exercise price and underlying shares for the PolyPid (PYPD) option grant?

The granted options carry an exercise price of $4.4600 per share. They are options on 75,000 underlying Ordinary Shares of PolyPid Ltd., providing the right to buy those shares at that fixed price once vested and exercised before expiration.

What is the vesting schedule of the PolyPid (PYPD) stock options granted to the Deputy CEO?

The options vest on a quarterly basis beginning May 11, 2026 and continuing until May 11, 2030. This means the 75,000-option grant becomes exercisable in installments over that four-year period rather than all at once on the grant date.

When do the newly granted PolyPid (PYPD) stock options expire?

The granted stock options have an expiration date of May 11, 2036. Any portion of the 75,000 options that has vested but is not exercised by that date will lapse, according to the terms reported with this derivative securities award.

What holdings after the transaction does the PolyPid (PYPD) Form 4 show for the Deputy CEO?

After this grant, the Form 4 reports that Dalit Fellous Hazan directly holds 75,000 derivative securities of this type. This figure reflects the total stock options of the reported series following the May 11, 2026 award transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hazan Dalit Fellous

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Deputy CEO, EVP, RD, CRA

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	05/11/2026		A		75,000		08/11/2026(1)	05/11/2036	Ordinary Shares	75,000	$4.46	75,000	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.

	/s/ Hazan Dalit Fellous	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)